Data from the Phase III EMERGE trial show treatment with Symbravo provided more rapid and sustained migraine relief with ...

Perspectives of Lymphoma Survivors and Oncology Care Providers on Survivorship Care: A Qualitative Study Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment ... as advocate for ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Angiotensin-converting enzyme (ACE) inhibitors are oral medications that lower blood pressure. They are used to treat a variety of heart-related conditions including high blood pressure, coronary ...

In older adults with diabetes, GLP-1 receptor agonists were tied to a slightly lower risk for depression compared with one ...

Sotagliflozin significantly reduces heart attacks and strokes in high-risk patients with diabetes and kidney disease, ...

Ensho Therapeutics has presented additional data supporting NSHO-101, also referred to as EA1080, as an oral one-time-a-day ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM) announced that the EMERGE Phase 3 trial of Symbravo (MoSEIC meloxicam and rizatriptan ...

This new agent, like the other DPP-4 inhibitors, has a mechanism of action that affects both pancreatic ß-cell survival as well as ß-cell secretory function. These medications do not incite ...

The following is a summary of “Remdesivir is active in vitro against tick-borne encephalitis virus and selects for resistance ...

It’s clear the new MAHA Commission wants to focus on pediatric mental health. What’s not clear is exactly what that means and ...

Zongertinib, an investigational treatment for HER2-mutant advanced NSCLC, has received FDA priority review, showing positive ...